SCHEMBL14978147

SCHEMBL14978147

CCCCCCC(=O)N1C[C@H](O)C[C@H]1COC(c1ccccc1)(c1ccc(OC)cc1)c1ccc(OC)cc1

nearest known ligand 0.42

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
SLC6A11 P48066 6/20 0.42
SLC6A1 P30531 3/20 0.42
MEN1 O00255 3/20 0.40
KMT2A Q03164 3/20 0.40
MAPT P10636 1/20 0.40
MTNR1B P49286 2/20 0.38
TP53 P04637 2/20 0.38
CYP1A2 P05177 1/20 0.38
CYP3A4 P08684 1/20 0.38
SLC6A12 P48065 1/20 0.38
SLC6A13 Q9NSD5 1/20 0.38
MMP1 P03956 1/20 0.36
MMP3 P08254 1/20 0.36
MMP7 P09237 1/20 0.36
MMP9 P14780 1/20 0.36
MMP13 P45452 1/20 0.36
KDM4E B2RXH2 1/20 0.36
TYMP P19971 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9908638 1.00 SLC6A11 (0.42) SLC6A11SLC6A1MEN1KMT2AMAPT
SCHEMBL26302691 1.00 SLC6A11 (0.42) SLC6A11SLC6A1MEN1KMT2AMAPT
SCHEMBL26302681 1.00 SLC6A11 (0.42) SLC6A11SLC6A1MEN1KMT2AMAPT
SCHEMBL26302685 1.00 SLC6A11 (0.42) SLC6A11SLC6A1MEN1KMT2AMAPT
SCHEMBL9908645 0.99 SLC6A11 (0.42) SLC6A11SLC6A1MEN1KMT2AMAPT
SCHEMBL26302692 0.95 CNR1 (0.42) SLC6A11SLC6A1MEN1KMT2AMAPT
SCHEMBL24383294 0.94 SLC6A11 (0.42) SLC6A11SLC6A1MEN1KMT2ATP53
SCHEMBL9604514 0.94 SLC6A11 (0.42) SLC6A11SLC6A1MEN1KMT2ATP53
SCHEMBL16843276 0.94 SLC6A11 (0.42) SLC6A11SLC6A1MEN1KMT2ATP53
SCHEMBL17231722 0.94 SLC6A11 (0.42) SLC6A11SLC6A1MEN1KMT2ATP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180208927-A1 MULTI-TARGETED SINGLE ENTITY CONJUGATES ALNYLAM PHARMACEUTICALS, INC. (US) 2018-07-26 US disclosed
US-9370581-B2 Carbohydrate conjugates as delivery agents for oligonucleotides ALNYLAM PHARMACEUTICALS, INC. (US) 2016-06-21 US disclosed
US-9370582-B2 Carbohydrate conjugates as delivery agents for oligonucleotides ALNYLAM PHARMACEUTICALS, INC. (US) 2016-06-21 US disclosed
US-9352048-B2 Carbohydrate conjugates as delivery agents for oligonucleotides ALNYLAM PHARMACEUTICALS, INC. (US) 2016-05-31 US disclosed
US-9290760-B2 Modified iRNA agents ALNYLAM PHARMACEUTICALS, INC. (US) 2016-03-22 US disclosed
US-20150119445-A1 Carbohydrate Conjugates as Delivery Agents for Oligonucleotides BANK OF AMERICA, N.A. 2015-04-30 US disclosed
US-20150119444-A1 Carbohydrate Conjugates as Delivery Agents for Oligonucleotides BANK OF AMERICA, N.A. 2015-04-30 US disclosed
US-20150011615-A1 Carbohydrate Conjugates as Delivery Agents for Oligonucleotides BANK OF AMERICA, N.A. 2015-01-08 US disclosed
US-8828956-B2 Carbohydrate conjugates as delivery agents for oligonucleotides ALNYLAM PHARMACEUTICALS, INC. (US) 2014-09-09 US disclosed
US-20130178512-A1 CARBOHYDRATE CONJUGATES AS DELIVERY AGENTS FOR OLIGONUCLEOTIDES ALNYLAM PHARMACEUTICALS, INC (US) 2013-07-11 US disclosed
US-8450467-B2 Carbohydrate conjugates as delivery agents for oligonucleotides ALNYLAM PHARMACEUTICALS, INC. (US) 2013-05-28 US disclosed
US-20120136042-A1 CARBOHYDRATE CONJUGATES AS DELIVERY AGENTS FOR OLIGONUCLEOTIDES ALNYLAM PHARMACEUTICALS, INC (US) 2012-05-31 US disclosed
US-8106022-B2 Carbohydrate conjugates as delivery agents for oligonucleotides ALNYLAM PHARMACEUTICALS, INC. (US) 2012-01-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130178512-A1 CARBOHYDRATE CONJUGATES AS DELIVERY AGENTS FOR OLIGONUCLEOTIDES LPXN, ZYX, OSTC SLC6A11 2103/4885SLC6A1 3179/4885MEN1 4655/4885
US-20150119445-A1 Carbohydrate Conjugates as Delivery Agents for Oligonucleotides LPXN, ZYX, OSTC SLC6A11 2070/4885SLC6A1 3171/4885MEN1 4674/4885
US-20150011615-A1 Carbohydrate Conjugates as Delivery Agents for Oligonucleotides LPXN, ZYX, OSTC SLC6A11 2132/4885SLC6A1 3200/4885MEN1 4645/4885
US-20150119444-A1 Carbohydrate Conjugates as Delivery Agents for Oligonucleotides LPXN, ZYX, OSTC SLC6A11 2132/4885SLC6A1 3200/4885MEN1 4645/4885
US-20120136042-A1 CARBOHYDRATE CONJUGATES AS DELIVERY AGENTS FOR OLIGONUCLEOTIDES LPXN, ZYX, OSTC SLC6A11 2103/4885SLC6A1 3179/4885MEN1 4655/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.